

Hossein Haji Ali Afzali

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2489984/publications.pdf>

Version: 2024-02-01

34
papers

720
citations

566801

15
h-index

552369

26
g-index

34
all docs

34
docs citations

34
times ranked

1168
citing authors

#	ARTICLE	IF	CITATIONS
1	The representation of public values in health technology assessment to inform funding decisions: the case of Australia's national funding bodies. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e22.	0.2	4
2	Expediting Patient Access to New Health Technologies: Role of Disease-Specific Reference Models. <i>Value in Health</i> , 2021, 24, 755-758.	0.1	3
3	Improving Decision-Making Processes in Health: Is It Time for (Disease-Specific) Reference Models?. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 1-4.	1.0	5
4	Are the benefits of new health services greater than their opportunity costs?. <i>Australian Health Review</i> , 2019, 43, 508-510.	0.5	3
5	Lifetime costs of invasive meningococcal disease: A Markov model approach. <i>Vaccine</i> , 2019, 37, 6885-6893.	1.7	8
6	Structuring a conceptual model for cost-effectiveness analysis of frailty interventions. <i>PLoS ONE</i> , 2019, 14, e0222049.	1.1	11
7	Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. <i>Vaccine</i> , 2019, 37, 2768-2782.	1.7	121
8	The development of funding recommendations for health technologies at the state level: A South Australian case study. <i>International Journal of Health Planning and Management</i> , 2018, 33, 806-822.	0.7	1
9	Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System. <i>Pharmacoeconomics</i> , 2018, 36, 239-252.	1.7	153
10	Model Structuring for Economic Evaluations of New Health Technologies. <i>Pharmacoeconomics</i> , 2018, 36, 1309-1319.	1.7	13
11	Is the Counterweight Program a feasible and acceptable option for structured weight management delivered by practice nurses in Australia? A mixed-methods study. <i>Australian Journal of Primary Health</i> , 2017, 23, 348.	0.4	4
12	A Cost-Effectiveness Model for Frail Older Persons: Development and Application to a Physiotherapy-Based Intervention. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 635-645.	1.0	10
13	Adolescent values for immunisation programs in Australia: A discrete choice experiment. <i>PLoS ONE</i> , 2017, 12, e0181073.	1.1	21
14	Adolescent confidence in immunisation: Assessing and comparing attitudes of adolescents and adults. <i>Vaccine</i> , 2016, 34, 5595-5603.	1.7	11
15	Should the Lambda (λ) Remain Silent?. <i>Pharmacoeconomics</i> , 2016, 34, 323-329.	1.7	6
16	Governments Need Better Guidance to Maximise Value for Money: The Case of Australia's Pharmaceuticals Benefits Advisory Committee. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 401-407.	1.0	14
17	Exploring Structural Uncertainty in Model-Based Economic Evaluations. <i>Pharmacoeconomics</i> , 2015, 33, 435-443.	1.7	24
18	Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions. <i>Pharmacoeconomics</i> , 2015, 33, 777-781.	1.7	8

#	ARTICLE	IF	CITATIONS
19	Practice nurse involvement in general practice clinical care: policy and funding issues need resolution. <i>Australian Health Review</i> , 2014, 38, 301.	0.5	18
20	Community, parental and adolescent awareness and knowledge of meningococcal disease. <i>Vaccine</i> , 2014, 32, 2042-2049.	1.7	23
21	Practice nurse involvement in primary care depression management: an observational cost-effectiveness analysis. <i>BMC Family Practice</i> , 2014, 15, 10.	2.9	5
22	The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children. <i>Vaccine</i> , 2014, 32, 4791-4798.	1.7	31
23	When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES. <i>Pharmacoeconomics</i> , 2014, 32, 547-558.	1.7	51
24	The Clinical Burden And Predictors of Sequelae Following Invasive Meningococcal Disease In Australian Children. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 316-318.	1.1	25
25	Model Performance Evaluation (Validation and Calibration) in Model-based Studies of Therapeutic Interventions for Cardiovascular Diseases. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 85-93.	1.0	18
26	A Model-Based Economic Evaluation of Improved Primary Care Management of Patients with Type 2 Diabetes in Australia. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 661-670.	1.0	6
27	Improving the Accuracy and Comparability of Model-Based Economic Evaluations of Health Technologies for Reimbursement Decisions. <i>Medical Decision Making</i> , 2013, 33, 325-332.	1.2	31
28	A Critical Review of Model-Based Economic Studies of Depression. <i>Pharmacoeconomics</i> , 2012, 30, 461-482.	1.7	28
29	A proposed model for economic evaluations of major depressive disorder. <i>European Journal of Health Economics</i> , 2012, 13, 501-510.	1.4	16
30	A model-based evaluation of collaborative care in management of patients with type 2 diabetes in Australia: an initial report. <i>Australian Health Review</i> , 2012, 36, 258.	0.5	4
31	Evaluation of collaborative models of care in the management of patients with depression: protocol and progress. <i>Mental Health in Family Medicine</i> , 2012, 9, 91-7.	0.2	1
32	Addressing the Challenge for Well Informed and Consistent Reimbursement Decisions. <i>Pharmacoeconomics</i> , 2011, 29, 823-825.	1.7	16
33	Exploring health professionals' perspectives on factors affecting Iranian hospital efficiency and suggestions for improvement. <i>International Journal of Health Planning and Management</i> , 2011, 26, e17-29.	0.7	6
34	A conceptual framework for selecting the most appropriate variables for measuring hospital efficiency with a focus on Iranian public hospitals. <i>Health Services Management Research</i> , 2009, 22, 81-91.	1.0	21